Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lukas BiomedicalROCO:6814 +4.45%66 Gross Margin % is 61.30% as of Dec. 2025, which is 2% above its 10-year median of 59.85. GuruFocus rates ROCO:6814 with a GF Score™ of 66/100 and a GF Value™ of NT$21.77 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 733 Biotechnology companies, Lukas Biomedical ranks worse than 51.02% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Lukas Biomedical had a gross margin of 61.30% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Lukas Biomedical Gross Margin % Related Terms
Lukas Biomedical Gross Margin % Historical Data
* Premium members only.
The historical data trend for Lukas Biomedical's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6814 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Lukas Biomedical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lukas Biomedical Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lukas Biomedical's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Lukas Biomedical's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Lukas Biomedical (ROCO:6814) has a Gross Margin % of 61.30% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Lukas Biomedical and its competitors. This is near median its historical median of 59.85. Over the past decade, Lukas Biomedical's Gross Margin % has ranged from 52.98 to 65.51. According to the industry distribution chart, Lukas Biomedical ranks #374 out of 733 companies in the Biotechnology industry, placing it in the top 51%.
Is Lukas Biomedical's Gross Margin % too high?
Lukas Biomedical's current Gross Margin % of 61.30% is near median its 10-year median of 59.85. Over the past 10 years, this metric has ranged from a low of 52.98 to a high of 65.51. The Biotechnology industry median Gross Margin % is 60.91. Lukas Biomedical's value of 61.30% is 0.6% above this industry median. Based on the distribution chart, Lukas Biomedical ranks #374 out of 733 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lukas Biomedical has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lukas Biomedical's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lukas Biomedical ranks #374 out of 733 companies for Gross Margin %. This places Lukas Biomedical in the lower half of its industry. The industry median Gross Margin % is 60.91. Lukas Biomedical's value of 61.30% is 0.6% above this benchmark. Historically, Lukas Biomedical's own Gross Margin % has ranged from 52.98 to 65.51 over the past decade. While the company's 10-year median is 59.85 vs. the industry median of 60.91, Lukas Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lukas Biomedical's current Gross Margin % of 61.30% is 0.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Lukas Biomedical and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lukas Biomedical's current Gross Margin % is 61.30%, which is near median its own 10-year median of 59.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lukas Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lukas Biomedical (ROCO:6814) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$21.77, compared to a current price of NT$24.65 — trading 13.2% above its estimated fair value. The current Gross Margin % is 61.30%, which is near median its 10-year median of 59.85 and 0.6% above the Biotechnology industry median of 60.91. Lukas Biomedical's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Lukas Biomedical (ROCO:6814), the current Gross Margin % is 61.30% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lukas Biomedical (ROCO:6814) Overvalued in 2026?
Based on GuruFocus' analysis, Lukas Biomedical stock appears to be overvalued.
The current stock price of NT$24.65 is trading 13.2% above its estimated GF Value™ of NT$21.77.
GuruFocus considers Lukas Biomedical to be Modestly Overvalued.
Key valuation signals for ROCO:6814:
Gross Margin %: 61.30% (near median its 10-year median of 59.85)
GF Value™: NT$21.77 vs. price of NT$24.65 (13.2% above fair value)
Industry Position: 0.6% above the Biotechnology median (#374 of 733)
No single metric tells the full story. See the ROCO:6814 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lukas Biomedical Inc. is engaged in researching and developing immunotherapy for cancer treatment technologies. The company's main business activities include developing immunocellular therapy, leasing and selling medical equipment, and selling biotech beauty products.
66GF Score
Get the complete analysis for ROCO:6814
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6814 has been successfully added to your 
